Overview
Presentations
Tricida, Inc. , is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.
News Releases
News
Events
Events
SEC Filings
| Filing date | Description | Form | View |
|---|---|---|---|
Statement of changes in beneficial ownership of securities |
4 | View HTML | |
Statement of changes in beneficial ownership of securities |
4 | View HTML | |
Statement of changes in beneficial ownership of securities |
4 | View HTML | |
Statement of changes in beneficial ownership of securities |
4 | View HTML | |
Statement of changes in beneficial ownership of securities |
4 | View HTML |
Stock Information
Data Provided by Refinitiv. Minimum 15 minutes delayed.
FAQs
7000 Shoreline Court, Suite 201
South San Francisco, CA 94080
Computershare Trust Company, N.A. is the transfer agent and registrar for the common stock of Tricida. Please contact Computershare as follows:
Regular Delivery:
Computershare
P.O. Box 505000
Louisville, KY 40233-5000
By Overnight Delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202
Online:
Computershare Investor Services:
www.computershare.com/investor
Phone:
(800) 736-3001 (US, Canada, Puerto Rico)
(781) 575-3100 (non-US)
Email:
web.queries@computershare.com
To change the address on your shareholder account you must send both your old and new addresses to our transfer agent at the following address:
Computershare
462 South 4th Street
Louisville, KY 40202